JP2015527316A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527316A5
JP2015527316A5 JP2015521033A JP2015521033A JP2015527316A5 JP 2015527316 A5 JP2015527316 A5 JP 2015527316A5 JP 2015521033 A JP2015521033 A JP 2015521033A JP 2015521033 A JP2015521033 A JP 2015521033A JP 2015527316 A5 JP2015527316 A5 JP 2015527316A5
Authority
JP
Japan
Prior art keywords
hdac4
group
combination
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015521033A
Other languages
English (en)
Japanese (ja)
Other versions
JP6393682B2 (ja
JP2015527316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FI2013/050745 external-priority patent/WO2014009609A1/en
Publication of JP2015527316A publication Critical patent/JP2015527316A/ja
Publication of JP2015527316A5 publication Critical patent/JP2015527316A5/ja
Application granted granted Critical
Publication of JP6393682B2 publication Critical patent/JP6393682B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015521033A 2012-07-13 2013-07-11 併用療法iii Expired - Fee Related JP6393682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20125795 2012-07-13
FI20125795 2012-07-13
PCT/FI2013/050745 WO2014009609A1 (en) 2012-07-13 2013-07-11 Combination therapy iii

Publications (3)

Publication Number Publication Date
JP2015527316A JP2015527316A (ja) 2015-09-17
JP2015527316A5 true JP2015527316A5 (https=) 2016-09-01
JP6393682B2 JP6393682B2 (ja) 2018-09-19

Family

ID=48917570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521033A Expired - Fee Related JP6393682B2 (ja) 2012-07-13 2013-07-11 併用療法iii

Country Status (8)

Country Link
US (1) US10166241B2 (https=)
EP (1) EP2872631B1 (https=)
JP (1) JP6393682B2 (https=)
CN (1) CN104619845A (https=)
CA (1) CA2878873C (https=)
DK (1) DK2872631T3 (https=)
ES (1) ES2627500T3 (https=)
WO (1) WO2014009609A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344923B (zh) * 2016-09-23 2019-09-27 中国人民解放军第二军医大学第二附属医院 组蛋白去乙酰化酶-4抑制剂在制备治疗多发性骨髓瘤疾病药物中的应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
AU2003211576A1 (en) * 2002-02-20 2003-09-09 Sueharu Horinouchi Histone deacetylase inhibitors and process for producing the same
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20050008617A1 (en) 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US20040077084A1 (en) 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
CA2523517C (en) 2003-04-25 2013-07-30 Dana-Farber Cancer Institute, Inc. Bcl2l12 polypeptide activators and inhibitors
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
WO2005011598A2 (en) 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
AU2006210994A1 (en) * 2005-02-07 2006-08-10 Topotarget Uk Limited Assays for agents with selective cytotoxicty to HDAC resistant cell lines
US20080021198A1 (en) 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8222423B2 (en) * 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
GB0612542D0 (en) 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
AU2007333799A1 (en) * 2006-12-15 2008-06-26 Novartis Ag Heterocycle compounds and methods of use thereof
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EA018618B1 (ru) * 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
US20090274682A1 (en) 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌

Similar Documents

Publication Publication Date Title
JP2015511638A5 (https=)
JP2014505107A5 (https=)
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
WO2013007708A1 (en) Medicament for treatment of liver cancer
JP2013510120A5 (https=)
JP2016040288A5 (https=)
SI3057959T1 (en) DNA-PK INHIBITORS
JP2008535902A5 (https=)
CL2008001898A1 (es) Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma.
JP2017527532A5 (https=)
JP2011006480A5 (https=)
JP2011509949A5 (https=)
JP2011515397A5 (https=)
JP2014511892A5 (https=)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2013510123A5 (https=)
JP2015531747A5 (https=)
RU2016110096A (ru) Новое хинолин-замещенное соединение
JP2011057693A5 (https=)
JP2008528468A5 (https=)
JP2011507896A5 (https=)
JP2015524472A5 (https=)
JP2013537905A5 (https=)
JP2015509102A5 (https=)